The Business Post Weekly Intelligence Briefing
Week of 5–11 February 2026: Deals, Distress & the Data Behind the Headlines
Source: ARTICLES | Period: 2026-02-05 to 2026-02-11
Weekly Intelligence Briefing | 5-11 February 2026
Galway Medtech Raises EUR62.5m, an Austrian Bank Eyes PTSB, and Dublin Airport Gets Its Freedom
A Galway medtech raised EUR62.5 million, an Austrian bank signalled it has billions to spend on Irish acquisitions, and the Cabinet moved to lift the 32-million passenger cap throttling Dublin Airport - all in a single week that generated 191 articles across Business Post platforms. The pattern: Ireland's indigenous innovation economy is maturing, its banking sector is consolidating, and its infrastructure constraints are being dismantled.
EUR62.5m
Neurent Medical Series C
EUR1.5bn+
Bawag Excess Capital by 2028
36m+
Dublin Airport 2025 Passengers
$31.17bn
Smurfit Westrock 2025 Revenue
By the Numbers
| Metric | Value | Signal |
|---|
| Neurent Medical Series C raise | EUR62.5m | Growth |
| Circit fintech raise | EUR18.4m | Growth |
| Smurfit Westrock 2025 net sales | $31.17bn (+47% YoY) | Standout |
| Smurfit Westrock job cuts | 3,000 | Restructuring |
| Solar 21 investor losses | EUR250m+ | Distress |
| AIB 2026 NII forecast (Carraighill) | EUR3.9bn (+EUR160m vs consensus) | Bullish |
| PTSB valuation range | EUR1.1bn-EUR2.26bn | M&A Watch |
| Ireland M&A total deal value 2025 | EUR19.5bn (-35% YoY) | Megadeal gap |
Business Post AI Pick: The week's defining tension is between two Irish companies at opposite ends of the lifecycle curve.
Neurent Medical Limited - registered December 2015, now backed by EUR62.5m in Series C capital - is scaling a non-surgical ENT device globally. Meanwhile, Nova Leah, a Dundalk cybersecurity medtech that raised over EUR4m from Enterprise Ireland and venture funds, called a creditors meeting this week as it moves toward liquidation. Both are Irish medtech. Both raised institutional capital. The difference: one found a commercial path, one did not. That gap is the story of Irish deep tech in 2026.
Pattern of the Week: Irish banking is entering a consolidation phase that will reshape the sector. AIB and Bank of Ireland are sitting on surplus capital so large they must pay out more than 100% of net income to reduce their ratios. Meanwhile, Austrian bank Bawag - with EUR1.5bn in excess capital by 2028 - is circling PTSB. The government still owns 57.5% of PTSB. A foreign acquisition of a state-owned Irish bank would be a structural shift not seen since the post-crash era.
The Investigation: Five Themes That Defined the Week
This week's Business Post coverage broke across five distinct themes: Irish tech and medtech funding, banking consolidation, infrastructure politics, corporate distress, and global market turbulence. The official record enriches each of them - sometimes confirming the story, sometimes adding a layer the article alone could not provide.
Top Stories by Theme
| Theme | Lead Story | Key Figure | Signal |
|---|
| Medtech Funding | Neurent Medical EUR62.5m Series C | Brian Shields, CEO | Galway medtech scaling globally |
| Fintech Funding | Circit EUR18.4m US expansion | David Heath, CEO | Irish audit tech going global |
| Banking M&A | Bawag eyes PTSB acquisition | Anas Abuzaakous, Bawag CEO | Consolidation watch |
| Infrastructure | Dublin Airport cap removed by Cabinet | Michael O'Leary, Ryanair | Connectivity unlocked |
| Corporate Distress | Solar 21 liquidation proceeds | Patrick O'Connell, RSM Ireland | EUR250m investor losses |
| Markets | Smurfit Westrock $31.17bn revenue | Tony Smurfit, CEO | Soft outlook despite scale |
| Legal Regulatory | Defamation Bill passes Oireachtas | Jim O'Callaghan, Justice Minister | Press freedom milestone |
| Tech AI | OpenAI hires EMEA sales chief in Dublin | Sanj Bhayro, OpenAI | Dublin AI hub deepening |
Standout: Ireland's M&A Market Held Up Without Megadeals The Business Post reported that Ireland's total M&A deal value fell 35% to EUR19.5 billion in 2025 - but that headline number is misleading. Mid-sized deals (EUR5m-EUR250m) accounted for 90% of disclosed transactions, and private equity volumes actually rose from 92 to 100 deals. The energy, mining and utilities sector led by value at EUR4.8 billion. The so what: Ireland's deal market is broadening its base, becoming less dependent on the occasional tech megadeal that dominated 2024. That is a more resilient foundation for 2026.
Stress Signal: Solar 21's EUR250m Collapse Reaches Its Endgame Investors in troubled energy firm Solar 21 - who are owed more than EUR250 million - relented this week on their objections to RSM Ireland liquidators Patrick O'Connell and Tom Robinson. The High Court made a winding-up order for EFW 21 Renewable Energy (Ireland) Limited. This is the final chapter of a years-long saga of delayed renewable energy projects. The lesson for Irish investors in early-stage energy infrastructure: project delays compound into existential risk.
Sector Breakdown: Where the Coverage Concentrated
Banking and Financial Services
~35 articlesMarkets and Equities
~30 articlesTech and Medtech
~25 articlesAviation and Infrastructure
~15 articlesLegal and Regulatory
~12 articlesReporter Breakdown: Who Drove the Week
| Reporter | Articles | Primary Beat |
|---|
| Alice O'Leary | 69 | Markets, global business, breaking news |
| Oisin Gaffey | 16 | Markets wrap, equities |
| Matthew Joyce | 11 | News briefs, politics |
| Vish Gain | 11 | Tech, markets |
| Charlie Taylor | 7 | Tech funding, startups |
| Emma Hanrahan | 7 | Commercial real estate, M&A |
| Donal MacNamee | 6 | Banking, finance |
Editorial Pattern: Alice O'Leary's 69 articles - 36% of the week's total output - reflects the Business Post's model of rapid-fire global market coverage alongside deeper Irish business analysis. Charlie Taylor's seven tech pieces drove the most original Irish business intelligence: both the Neurent Medical and Circit funding stories came from his beat. Donal MacNamee's six banking pieces - covering AIB pay deals, Bawag's PTSB ambitions, and the Carraighill forecasts - collectively form the most consequential Irish business narrative of the week.
The Connections: What the Official Record Adds to the Headlines
Articles are the starting point. The CRO register, the courts index, and the property register are where the real story lives. This week, cross-referencing Business Post coverage against official records reveals a Galway medtech with a complex VC capital structure, a banking sector sitting on capital it cannot deploy fast enough, and an infrastructure debate that has been running for nearly two decades.
Neurent Medical: The CRO Record Behind the EUR62.5m Headline Business Post reported that
Galway-based Neurent Medical raised EUR62.5m in a Series C round led by MVM Partners, with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland. CRO records tell a richer story.
Neurent Medical Limited (company number 573202) was incorporated on 9 December 2015 at Unit 1, Oran Point, Oranmore, Co. Galway - a decade-old company, not a startup. Its nominal share capital is just EUR1,461.44, but the CRO filing history shows multiple B5 Returns of Allotments - the mechanism by which VC investors receive shares - stretching from 2018 through September 2025. Three charges were registered in October 2024, suggesting a debt facility was drawn alongside the equity rounds. The company changed auditors in May 2025, and its constitution has been amended at least nine times - each amendment typically reflecting a new investor class or preference share structure. Director
Mark Fletcher is US-based (Asheville, NC), and
Drew Burdon is UK-based (Leeds) - reflecting the international investor base. The question for 2026 accounts: does the Neuromark product generate enough US commercial revenue to justify the capital structure?
Solar 21 and Nova Leah: Two Faces of Irish Deep Tech Distress The same week that Neurent Medical celebrated its EUR62.5m raise, two other Irish deep tech companies were in the courts and creditors rooms. Solar 21 - which owes Irish investors more than EUR250 million - reached its liquidation endgame as the High Court appointed RSM Ireland liquidators for EFW 21 Renewable Energy (Ireland) Limited. Separately, Nova Leah, a Dundalk cybersecurity firm providing risk assessment software for connected medical devices, called a creditors meeting to nominate Colin Gaynor of Resolute Advisory as liquidator. Nova Leah had raised over EUR4 million from Enterprise Ireland, Sure Valley Ventures, Cosimo, and Kernel Capital - and had won multiple awards including spinout company of the year. The pattern: Irish deep tech can attract institutional capital and win awards, but the gap between product-market fit and commercial scale remains the critical failure point.
Dublin Airport: A 19-Year Planning Constraint Finally Removed The Cabinet's decision to legislate for removal of the 32-million passenger cap at Dublin Airport - first imposed in 2007 as a planning condition for Terminal 2 - generated more Business Post coverage than any other single story this week. Articles by Ellie Donnelly and Fionn Thompson collectively capture the political, commercial, and geopolitical dimensions: Michael O'Leary criticising the government's timing, Willie Walsh calling the cap outdated, Airlines for America warning that uncertainty remains, and Ibec welcoming the move. Dublin Airport handled 36 million passengers in 2025 - already 4 million above the cap - meaning the cap was being breached in practice. The legislation is catching up with reality. The risk: An Coimisiun Pleanala must still conduct EU-required assessments before any ministerial order takes effect.
Irish Banking: Surplus Capital, Pay Deals, and a Foreign Suitor Three separate Business Post stories this week collectively paint a picture of an Irish banking sector that is simultaneously flush with capital and under pressure to deploy it. AIB struck a pay deal with the Financial Services Union - at least 3.5% or EUR1,500 minimum, plus a EUR1,000 tax-free voucher - while Carraighill forecast AIB's 2026 net interest income at EUR3.9 billion, EUR160 million above consensus. Bank of Ireland is expected to distribute 100% of its 2025 net income to shareholders. Meanwhile, Austrian bank Bawag - which already operates in Ireland through its MoCo branch - confirmed it has the bandwidth to execute deals in the EUR1-2 billion range and described the Irish market as one of the most robust in the EU. PTSB, which has been for sale since October 2025, is valued by analysts at between EUR1.1 billion and EUR2.26 billion. The Irish government owns 57.5% of PTSB. A Bawag acquisition would require the state to accept shares or cash - and the Department of Finance's appetite for a foreign bank acquiring a state-owned institution will be the defining political question of any deal.
AI in Ireland: OpenAI Builds, IMRO Fights Back Two AI stories this week sit at opposite ends of the spectrum. OpenAI hired Sanj Bhayro as head of sales for its EMEA hub in Dublin - a signal that the company is building out its European commercial operation from Ireland. Separately, the Irish Music Rights Organisation appeared before the Oireachtas Committee on Culture to push for a human-made label on creative content and legislation to protect copyright from AI training. The tension: Ireland is simultaneously the European headquarters for AI companies and the home of creative industries fighting for protection from those same companies. NewsBrands Ireland also warned that unchecked AI risks quietly destroying Irish democracy by undermining the financial model of quality journalism.
The Radar: Three Signals Worth Watching
Irish Medtech Entering Commercial Scale Phase Three Irish medtech companies made news this week:
Neurent Medical raised EUR62.5m for US commercial expansion, Tyndall National Institute joined a EUR50m European quantum chip project, and Nova Leah moved to liquidation. The pattern reflects a cohort of companies founded in 2012-2016 that are now either achieving commercial scale or failing to. Watch for: a wave of Series B and C raises from this cohort in 2026-2027, and a corresponding wave of liquidations from those that cannot cross the commercial threshold.
European Banking Consolidation Reaching Ireland Bawag's interest in PTSB is not an isolated event. Across Europe, mid-sized banks with surplus capital are looking for acquisition targets in markets with strong fundamentals. Ireland - with low unemployment, strong GDP growth, and a concentrated banking market - is an attractive target. The Irish government's willingness to sell its PTSB stake will signal whether Ireland is open to European banking consolidation or whether political considerations will block it. Watch for: formal bid documentation from Bawag in Q2 2026, and the government's response to any offer that involves share issuance rather than cash.
Dublin Airport Infrastructure: The Planning Gap The Cabinet has approved legislation to remove the passenger cap, but the actual removal requires An Coimisiun Pleanala to conduct EU-required environmental assessments. Airlines for America warned this week that the uncertainty has not been removed. The risk: if the planning process takes 12-18 months, airlines will not commit to new routes for the 2027 summer schedule. Watch for: the timeline for An Coimisiun Pleanala's assessment process and whether the government can fast-track the legislation before the summer recess.
The Deep Dive: Neurent Medical and Smurfit Westrock
Two companies dominated the week's business intelligence from very different vantage points. One is a decade-old Galway medtech that has just secured its largest funding round yet and is preparing to scale a non-surgical ENT device across the US market. The other is a packaging giant that posted a 47% revenue surge but is cutting 3,000 jobs and guiding cautiously for 2026. Together, they illustrate the two speeds at which Irish-connected business operates.
Neurent Medical - A Decade of Capital-Raising, Now at Commercial Scale
Neurent Medical Limited was incorporated on 9 December 2015 at Oranmore, Co. Galway (eircode H91D7X2), classified under NACE code Research and experimental development. Its co-founder and CEO is Brian Shields. The company's Neuromark device targets the overactive posterior nasal nerves that drive chronic rhinitis - a condition affecting millions globally. The EUR62.5m Series C, led by Boston-based MVM Partners with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland, will fund commercial expansion.
| Metric | Detail | Source |
|---|
| Incorporation date | 9 December 2015 | CRO |
| Registered address | Unit 1, Oran Point, Oranmore, Galway H91D7X2 | CRO |
| NACE classification | Research and experimental development | CRO |
| Nominal share capital | EUR1,461.44 issued | CRO |
| Charges registered | 3 charges, October 2024 | CRO |
| Constitution amendments | 9+ G1 special resolutions (VC share classes) | CRO |
| Series C raise | EUR62.5m (Feb 2026) | Business Post |
| Lead investor | MVM Partners (Boston) | Business Post |
Reading Between the Lines: The three charges registered in October 2024 - alongside multiple B5 allotments in the same period - suggest Neurent drew a debt facility alongside its pre-Series C equity round. This is a common structure for medtech companies approaching commercial scale: equity for R&D and regulatory, debt for commercial infrastructure. The nine-plus constitution amendments reflect the complexity of managing multiple investor classes across a decade of fundraising. The auditor change in May 2025 is worth watching - auditor changes at this stage sometimes precede a significant transaction. The question for 2026 accounts: does the Neuromark product generate enough US commercial revenue to justify the capital structure, and is an exit - trade sale or IPO - on the horizon?
The question for 2026: With three charges on the register and a new auditor, is Neurent Medical preparing for a trade sale to a major ENT device manufacturer, or is the Series C the last private round before a public listing?
Smurfit Westrock - Scale Without Momentum
Smurfit Westrock reported 2025 net sales of $31.17 billion - a 47% year-on-year increase, largely reflecting the full-year impact of the WestRock merger completed in 2024. But the headline number obscures a more cautious underlying story. Q4 2025 revenues were flat, net income fell, and the company guided for full-year 2026 EBITDA of $5.0-5.3 billion - a soft outlook that Goodbody analysts described as unsurprising given demand weakness. CEO Tony Smurfit will lay out a five-year strategic plan targeting $7 billion EBITDA by end-2030.
| Metric | 2025 | Signal |
|---|
| Net sales | $31.17bn (+47% YoY) | Scale achieved |
| Q4 net income | Declined vs prior year | Momentum weak |
| Job cuts announced | 3,000 | Restructuring |
| 2026 EBITDA guidance | $5.0-5.3bn | Soft |
| 2030 EBITDA target | $7bn | Ambitious |
Why It Matters: Smurfit Westrock is now one of the world's largest packaging companies, with Irish roots and a dual listing. The 3,000 job cuts reflect the reality that merging two large companies creates significant overlap. The $7 billion EBITDA target by 2030 implies roughly 32-40% growth from current guidance levels. That is achievable if the US packaging sector recovers and the company executes its integration. But the soft outlook for 2026 suggests the integration benefits are not yet flowing through. The question for 2026: will the five-year plan be credible enough to re-rate the stock, or will investors wait for evidence of demand recovery before buying in?
Key People This Period
| Name | Role | Notable Activity | Connections |
|---|
| Brian Shields | CEO/Co-founder, Neurent Medical | Led EUR62.5m Series C raise; CRO secretary 2015-2022 | Neurent Medical Ltd |
| Tony Smurfit | CEO, Smurfit Westrock | $31.17bn revenue; 3,000 job cuts; 5-year $7bn EBITDA plan | Smurfit Westrock (NYSE/LSE) |
| Colin Hunt | CEO, AIB | Pay deal with FSU; Carraighill forecasts EUR3.9bn NII | AIB Group |
| Michael O'Leary | CEO, Ryanair | Criticised government timing on airport cap; CFM engine deal | Ryanair; DAA; Aer Lingus |
| Willie Walsh | Director General, IATA | Called Dublin Airport cap outdated; wants early results | IATA; DAA; Aer Lingus (former) |
| Albert Manifold | Chair, BP | Suspended share buyback; steering BP's strategic reset | BP; CRH (former CEO) |
| Sanj Bhayro | Head of Sales EMEA, OpenAI | Hired to build out OpenAI's Dublin EMEA hub from January 2026 | OpenAI Dublin |
| Anita Finnegan | Founder, Nova Leah | Cybersecurity medtech moving to liquidation after EUR4m raised | Nova Leah; Enterprise Ireland |
One to Watch: Circit
Circit - Irish Audit Fintech Targeting the US Market
Fintech | Dublin | CEO: David Heath | Series B: EUR18.4m (Feb 2026)
| Metric | Value |
|---|
| Series B raise (Feb 2026) | EUR18.4m |
| Lead investor | Ten Coves Capital (New York) |
| Audit firms using platform | 400+, including all top 20 global networks |
| Bank and institution connections | 30,000+ |
| Focus market | US (2026 expansion) |
Circit provides a platform that automates audit workflows using open banking to verify ownership of assets and liabilities. It connects audit firms directly to financial institutions' systems, replacing the manual confirmation process that has been a bottleneck in audit for decades.
Why it matters: Circit is not a consumer fintech - it is B2B infrastructure for the audit profession, a market that moves slowly but, once adopted, is deeply sticky. The fact that all top 20 global audit networks are already using the platform suggests the product has cleared the hardest hurdle: institutional adoption. The EUR18.4m raise, led by Ten Coves Capital - a New York firm that backed Plaid - signals that US investors see Circit as a potential category leader in audit automation. The number that matters: 30,000 banks and financial institutions connected to the platform. That network effect is the moat. Watch for: a US revenue milestone announcement in H2 2026 and a potential Series C within 18 months.
The Broader Picture: Courts, Property, and the Week Ahead
The Irish Courts
The High Court delivered 11 judgments in the week of 5-11 February 2026. The most business-relevant was a Revenue Commissioners case on capital gains tax avoidance, delivered on the first day of the week. Three planning-related judgments - including two involving An Coimisiun Pleanala - reflect the continued pressure on Ireland's planning system from judicial review challenges, relevant context for the Dublin Airport cap debate playing out in the same week.
| Citation | Parties | Subject | Why It Matters |
|---|
| [2026] IEHC 59 | Hegarty, Geary, Ward v Revenue Commissioners | CGT tax avoidance - deductibility of advisor fees; hedging instruments | Clarifies limits of CGT loss planning; relevant to high-net-worth tax structuring |
| [2026] IEHC 67 | McDonald v Minister for Housing No.3 | Housing and planning challenge - third in series | Ongoing judicial scrutiny of housing policy decisions |
| [2026] IEHC 65 | Hoctor v An Coimisiun Pleanala | Planning permission challenge | Adds to backlog of planning judicial reviews - systemic pressure on planning system |
| [2026] IEHC 71 | Chimwala v Residential Tenancies Board | Tenancy dispute - RTB jurisdiction | Reflects continued pressure on rental market dispute resolution |
Tax Avoidance Watch: The Hegarty v Revenue Commissioners judgment - delivered on 5 February 2026 - addresses CGT tax avoidance through hedging instruments and the deductibility of advisor fees. The case involved three separate taxpayers and engaged the Tax Appeals Commissioner, the High Court, and principles from UK tax avoidance cases including Ramsay and Schofield. For business readers: this judgment will be closely studied by tax practitioners advising on capital gains planning. The Revenue Commissioners' success in this case signals continued aggressive enforcement of anti-avoidance provisions.
Property Markets and Plans
The Irish property register recorded 759 transactions in the week of 5-11 February 2026, with a national average price of EUR389,503 and a median of EUR344,453. Dublin transactions - 230 of the total - averaged EUR551,621, some 42% above the national average. The top transaction nationally reached EUR11.6 million. The commercial real estate story of the week was State Street's reported move to Denis O'Brien's 2 Grand Canal Quay development in Dublin's docklands - a 15-storey, 145,000 sq ft building with a proposed 15-year lease at approximately EUR60 per sq ft.
| Metric | National | Dublin |
|---|
| Total transactions | 759 | 230 |
| Average price | EUR389,503 | EUR551,621 |
| Median price | EUR344,453 | EUR481,714 |
| Maximum transaction | EUR11.6m | EUR2.2m |
| Dublin premium vs national | - | +42% |
Commercial Real Estate Signal: State Street's reported move to Denis O'Brien's 2 Grand Canal Quay development - at EUR60 per sq ft for 5,574-7,432 sq m on a 15-year term - is a significant vote of confidence in Dublin's docklands office market. State Street employs over 2,000 staff across Dublin, Kilkenny, Naas, and Drogheda. The return-to-office mandate the company recently communicated to Irish staff aligns with the move to a purpose-built, high-specification building. For the commercial property market: this deal, if confirmed, would be one of the larger office lettings in Dublin in 2026 and signals that major financial services firms are committing to long-term Dublin footprints despite hybrid working.
The Week Ahead
The week of 5-11 February 2026 was defined by three structural themes that will continue to develop in the coming weeks and months. First, Irish medtech and fintech are entering a commercial scale phase - the Neurent Medical and Circit raises are not isolated events but part of a cohort of companies founded in 2012-2016 that are now either achieving commercial scale or failing to. Second, Irish banking consolidation is accelerating - the Bawag-PTSB dynamic will dominate financial services coverage for the next six months. Third, Dublin Airport's infrastructure constraint is being dismantled - but the planning process will determine whether the legislation translates into new routes and economic activity in time for the 2027 summer schedule.
The Bottom Line: Ireland's economy in February 2026 is operating at two speeds. The indigenous innovation economy - medtech, fintech, deep tech - is maturing and attracting serious international capital. The infrastructure and institutional economy - airports, banks, planning systems - is catching up with a decade of underinvestment and over-regulation. The gap between these two speeds is the defining economic story of the year.
What to Watch: (1) Bawag's formal approach to PTSB - expected in Q2 2026 - and the government's response to any offer involving share issuance. (2) The An Coimisiun Pleanala assessment timeline for Dublin Airport cap removal - airlines need certainty before the 2027 summer schedule. (3) Neurent Medical's 2025 financial accounts, due by September 2026, which will show whether the Neuromark device is generating US commercial revenue at scale.
